Stocklytics Platform
Asset logo for symbol PDSB
PDS Biotechnology
PDSB39
$2.15arrow_drop_down2.27%-$0.05
Penny Stock
Asset logo for symbol PDSB
PDSB39

$2.15

arrow_drop_down2.27%

Performance History

Chart placeholder
Key Stats
Open$2.10
Prev. Close$2.09
EPS-1.23
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$75.75M
PE Ratio-
LOWHIGH
Day Range1.95
2.12
52 Week Range1.54
6.85
Ratios
Revenue-
EBITDA Margin %-
EPS-1.23

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About PDS Biotechnology (PDSB)

PDS Biotechnology Corp (PDSB) is a biotechnology company that focuses on developing novel immunotherapies for the treatment of various cancers and infectious diseases. The company's lead product candidate is PDS0101, a clinical-stage immunotherapy designed to treat human papillomavirus (HPV)-associated cancers. PDS0101 utilizes the company's proprietary Versamune platform, which enhances the immune response against the tumor cells. The company is also developing PDS0102, a dual-acting immunotherapy that targets HPV and other tumor-specific antigens.
PDSB stock price history shows that the stock has experienced fluctuations over time. Investors should take into account the volatility of the stock market when assessing the potential risks and rewards of investing in PDSB. It is important to make informed investment decisions based on thorough analysis of the company's financial performance and industry trends.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Frank K. Bedu-Addo Ph.D.
Headquarters
Florham Park
Employees
26
Exchange
NASDAQ
add PDS Biotechnology to watchlist

Keep an eye on PDS Biotechnology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is PDS Biotechnology's (PDSB) price per share?

The current price per share for PDS Biotechnology (PDSB) is $2.15. The stock has seen a price change of -$0.05 recently, indicating a -2.27% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for PDS Biotechnology (PDSB)?

For PDS Biotechnology (PDSB), the 52-week high is $6.85, which is 218.6% from the current price. The 52-week low is $1.54, the current price is 39.25% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is PDS Biotechnology (PDSB) a growth stock?

PDS Biotechnology (PDSB) has shown an average price growth of -6.03% over the past three years. It has received a score of 12 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying PDS Biotechnology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is PDS Biotechnology (PDSB) stock price performance year to date (YTD)?

As of the latest data, PDS Biotechnology (PDSB) has a year-to-date price change of -58.25%. Over the past month, the stock has experienced a price change of -31.09%. Over the last three months, the change has been -38.22%. Over the past six months, the figure is -39.61%. Looking at a longer horizon, the five-year price change stands at -0.92%.
help

Is PDS Biotechnology (PDSB) a profitable company?

PDS Biotechnology (PDSB) has a net income of -$42.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$43.05M. Furthermore, the EBITDA is -$39.65M.
help

What is the market capitalization of PDS Biotechnology (PDSB)?

PDS Biotechnology (PDSB) has a market capitalization of $82.3M. The average daily trading volume is 2.15, indicating the stock's liquidity and investor engagement.

News

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
PDS BIOTECH
VERSAMUNE® HPV
CERVICAL CANCER
CHEMORADIATION
Oct 2, 2024

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PDS BIOTECHNOLOGY
VERSAMUNE® HPV
KEYTRUDA®
HNSCC
ESMO CONGRESS 2024
Sep 9, 2024

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
CLINICAL STUDY
May 9, 2024

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotechnology Announces Details of Virtual KOL Event
CALENDAR OF EVENTS
May 3, 2024

PDS Biotechnology Announces Details of Virtual KOL Event

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
DIRECTORS AND OFFICERS
May 2, 2024

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
CLINICAL STUDY
Apr 23, 2024

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Take Your Investments to a Whole New Level